Collectively, our data demonstrate that the PRAME-targeting ImmTAC® can redirect T cells to selectively and efficiently kill PRAME+/HLA-A*02:01+ tumor cells with varying levels of PRAME expression and peptide presentation. The gene discussed is PRAME; the disease is neoplasm.